ADC Therapeutics Files to Sell 9.83M Common Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ADCT?
ADC Therapeutics files to sell 9.83M common shares for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADCT
Wall Street analysts forecast ADCT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.800
Low
5.00
Averages
7.33
High
10.00
Current: 4.800
Low
5.00
Averages
7.33
High
10.00
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADC Therapeutics Q4 2025 Earnings Call Insights
- Financial Performance Boost: ADC Therapeutics reported net product revenues of $22.3 million for Q4 2025, a 36% increase from $16.4 million in Q4 2024, indicating a solid market position and growth potential.
- Cost Structure Optimization: CEO Ameet Mallik highlighted a 50% reduction in operating costs through strategic focus, which not only enhanced financial flexibility but also strengthened competitive positioning, particularly in the third-line DLBCL market.
- Positive Future Outlook: The company expects to share LOTIS-5 top-line data in Q2 2026 and plans to submit a supplemental biologic license application in the first half of 2027, demonstrating confidence in future growth and strategic planning.
- Robust Cash Flow: At year-end, the company reported cash and cash equivalents of $261 million, expected to fund operations through at least 2028, reflecting strategic flexibility in ongoing investments and R&D.
See More
ADC Therapeutics Q4 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: ADC Therapeutics reported a Q4 non-GAAP EPS of -$0.05, indicating gradual financial improvement despite still being in the negative, which reflects potential stability in its business model.
- Revenue Growth: The company achieved Q4 revenue of $23.06 million, a 36.4% year-over-year increase, exceeding market expectations by $0.77 million, suggesting sustained demand for its products and laying a foundation for future profitability.
- Future Outlook: ADC Therapeutics anticipates approximately $73 million in revenue for 2025, demonstrating confidence in future growth that may attract more investor interest in its long-term potential.
- Market Reaction: Following the earnings release, ADC Therapeutics' stock price may experience positive momentum as investor confidence in its continued growth strengthens, potentially driving further advancements in the biopharmaceutical sector.
See More
ADC Therapeutics Reports 2025 Financial Results and Future Outlook
- Financial Performance: In Q4 2025, ADC Therapeutics reported net product revenue of approximately $22.3 million and $73.6 million for the full year, reflecting a 36% and 10% increase compared to 2024, indicating stable demand and improved pricing in the antibody-drug conjugate market.
- R&D Expenditure: The company incurred R&D expenses of $18.2 million in Q4 and $104 million for the full year 2025, down from $27.1 million and $109.6 million in 2024, primarily due to reduced spending on discontinued programs, showcasing a strategic focus on essential clinical trials.
- Cash Position: As of December 31, 2025, cash and cash equivalents stood at $261.3 million, providing a cash runway expected to last until at least 2028, which enhances the company's financial flexibility for future R&D and market expansion.
- Increased Strategic Flexibility: In February 2026, the company amended its financing agreement with HealthCare Royalty, reducing the change of control payment from $750 million to $150 million, thereby enhancing strategic flexibility in potential acquisition scenarios and supporting future growth initiatives.
See More
ADC Therapeutics to Announce Q4 Earnings on March 10
- Earnings Announcement: ADC Therapeutics is set to announce its Q4 earnings on March 10 before market open, with investors keenly awaiting the results to gauge the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.27, reflecting an 8% year-over-year decline, indicating challenges in profitability that may affect investor confidence.
- Revenue Projections: The expected revenue of $22.29 million represents a 31.8% year-over-year increase, showcasing a positive trend in sales growth that could lay the groundwork for future business expansion.
- Historical Performance Review: Over the past two years, ADC Therapeutics has only beaten revenue estimates 38% of the time and has not surpassed EPS estimates, highlighting volatility in its earnings forecasts and necessitating cautious evaluation of its financial health by investors.
See More
ADC Therapeutics to Host Q4 2025 Financial Results Call
- Conference Call Announcement: ADC Therapeutics will host a conference call on March 10, 2026, at 8:30 a.m. EDT to report its Q4 and full-year 2025 financial results, which is expected to positively influence investor confidence.
- ZYNLONTA Drug Progress: The company's ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma, showcasing its leadership in the ADC field.
- Global Operational Presence: Headquartered in Lausanne, Switzerland, with operations in New Jersey, ADC Therapeutics focuses on ADC development from clinical trials to manufacturing and commercialization, aiming to drive innovation and enhance market competitiveness.
- Forward-Looking Statement Risks: The press release highlights various risks and uncertainties associated with forward-looking statements that could lead to significant differences between actual results and expectations, urging investors to approach this information with caution.
See More
ADC Therapeutics Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: ADC Therapeutics will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, where CEO Ameet Mallik will present at 11:50 a.m. EST, which is expected to attract investor attention and enhance the company's visibility.
- One-on-One Meeting Opportunities: At the Jefferies Biotech on the Beach Summit on March 11, 2026, ADC Therapeutics will hold one-on-one meetings, a format that helps establish closer connections with potential investors, potentially facilitating future financing opportunities.
- Product Development Highlights: ADC Therapeutics' ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission, indicating the company's innovative capabilities in the field of antibody-drug conjugates, which is expected to drive sales growth and enhance market competitiveness.
- Global Business Layout: Headquartered in Lausanne, Switzerland, with operations in New Jersey, the company demonstrates its globalization strategy aimed at driving innovation in ADC development and further expanding its international market share.
See More
ADC Therapeutics Q4 2025 Earnings Call Insights
- Financial Performance Boost: ADC Therapeutics reported net product revenues of $22.3 million for Q4 2025, a 36% increase from $16.4 million in Q4 2024, indicating a solid market position and growth potential.
- Cost Structure Optimization: CEO Ameet Mallik highlighted a 50% reduction in operating costs through strategic focus, which not only enhanced financial flexibility but also strengthened competitive positioning, particularly in the third-line DLBCL market.
- Positive Future Outlook: The company expects to share LOTIS-5 top-line data in Q2 2026 and plans to submit a supplemental biologic license application in the first half of 2027, demonstrating confidence in future growth and strategic planning.
- Robust Cash Flow: At year-end, the company reported cash and cash equivalents of $261 million, expected to fund operations through at least 2028, reflecting strategic flexibility in ongoing investments and R&D.
See More
ADC Therapeutics Q4 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: ADC Therapeutics reported a Q4 non-GAAP EPS of -$0.05, indicating gradual financial improvement despite still being in the negative, which reflects potential stability in its business model.
- Revenue Growth: The company achieved Q4 revenue of $23.06 million, a 36.4% year-over-year increase, exceeding market expectations by $0.77 million, suggesting sustained demand for its products and laying a foundation for future profitability.
- Future Outlook: ADC Therapeutics anticipates approximately $73 million in revenue for 2025, demonstrating confidence in future growth that may attract more investor interest in its long-term potential.
- Market Reaction: Following the earnings release, ADC Therapeutics' stock price may experience positive momentum as investor confidence in its continued growth strengthens, potentially driving further advancements in the biopharmaceutical sector.
See More
ADC Therapeutics Reports 2025 Financial Results and Future Outlook
- Financial Performance: In Q4 2025, ADC Therapeutics reported net product revenue of approximately $22.3 million and $73.6 million for the full year, reflecting a 36% and 10% increase compared to 2024, indicating stable demand and improved pricing in the antibody-drug conjugate market.
- R&D Expenditure: The company incurred R&D expenses of $18.2 million in Q4 and $104 million for the full year 2025, down from $27.1 million and $109.6 million in 2024, primarily due to reduced spending on discontinued programs, showcasing a strategic focus on essential clinical trials.
- Cash Position: As of December 31, 2025, cash and cash equivalents stood at $261.3 million, providing a cash runway expected to last until at least 2028, which enhances the company's financial flexibility for future R&D and market expansion.
- Increased Strategic Flexibility: In February 2026, the company amended its financing agreement with HealthCare Royalty, reducing the change of control payment from $750 million to $150 million, thereby enhancing strategic flexibility in potential acquisition scenarios and supporting future growth initiatives.
See More
ADC Therapeutics to Announce Q4 Earnings on March 10
- Earnings Announcement: ADC Therapeutics is set to announce its Q4 earnings on March 10 before market open, with investors keenly awaiting the results to gauge the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.27, reflecting an 8% year-over-year decline, indicating challenges in profitability that may affect investor confidence.
- Revenue Projections: The expected revenue of $22.29 million represents a 31.8% year-over-year increase, showcasing a positive trend in sales growth that could lay the groundwork for future business expansion.
- Historical Performance Review: Over the past two years, ADC Therapeutics has only beaten revenue estimates 38% of the time and has not surpassed EPS estimates, highlighting volatility in its earnings forecasts and necessitating cautious evaluation of its financial health by investors.
See More
ADC Therapeutics to Host Q4 2025 Financial Results Call
- Conference Call Announcement: ADC Therapeutics will host a conference call on March 10, 2026, at 8:30 a.m. EDT to report its Q4 and full-year 2025 financial results, which is expected to positively influence investor confidence.
- ZYNLONTA Drug Progress: The company's ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma, showcasing its leadership in the ADC field.
- Global Operational Presence: Headquartered in Lausanne, Switzerland, with operations in New Jersey, ADC Therapeutics focuses on ADC development from clinical trials to manufacturing and commercialization, aiming to drive innovation and enhance market competitiveness.
- Forward-Looking Statement Risks: The press release highlights various risks and uncertainties associated with forward-looking statements that could lead to significant differences between actual results and expectations, urging investors to approach this information with caution.
See More
ADC Therapeutics Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: ADC Therapeutics will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, where CEO Ameet Mallik will present at 11:50 a.m. EST, which is expected to attract investor attention and enhance the company's visibility.
- One-on-One Meeting Opportunities: At the Jefferies Biotech on the Beach Summit on March 11, 2026, ADC Therapeutics will hold one-on-one meetings, a format that helps establish closer connections with potential investors, potentially facilitating future financing opportunities.
- Product Development Highlights: ADC Therapeutics' ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission, indicating the company's innovative capabilities in the field of antibody-drug conjugates, which is expected to drive sales growth and enhance market competitiveness.
- Global Business Layout: Headquartered in Lausanne, Switzerland, with operations in New Jersey, the company demonstrates its globalization strategy aimed at driving innovation in ADC development and further expanding its international market share.
See More
